A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3)

I4V-MC-JAHN -

The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis (eczema).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Atopic Dermatitis
What the trial is testing?
Baricitinib, Placebo
Could I receive a Placebo?
Yes
Enrollment Goal
1645
Trial Dates
Mar 28, 2018 - Jul 12, 2023
How long will I be in the trial?
Your participation could last up to 108 weeks and include up to 17 visits to the study center.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have met participation requirements for a previous atopic dermatitis (eczema) study

  • Participants must have completed the final treatment visit in a previous baricitinib atopic dermatitis (eczema) study

Participants Must Not:

  • Participants must not have permanently stopped taking baricitinib during a previous baricitinib study

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources